Form 4: Jazz Pharmaceuticals Executive Neena M Patil Reports Acquisition of Shares

Neena M Patil, EVP & Chief Legal Officer of Jazz Pharmaceuticals, reports the acquisition of 12,348 ordinary shares and subsequent holdings of 45,061 shares.

Summary

• Neena M Patil, an executive at Jazz Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2024, Patil acquired 12,348 ordinary shares at a price of $0.00.
• These shares were acquired through restricted stock units granted under the company's 2011 Equity Incentive Plan.
• Following the transaction, Patil directly owns 45,061 ordinary shares.
• The restricted stock units vest in equal annual installments over four years, starting March 5, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock options vesting. There's no indication of significant positive or negative news.

Positives

• The acquisition of shares by an executive could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document outlines the vesting schedule for the restricted stock units, indicating a continued equity stake for the executive over the next four years.

Industry Context

Executive stock ownership is a common practice in publicly traded companies and is often used to align management's interests with those of shareholders.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns executive interests with shareholder value.

Key Dates